Product Center
IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-30
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly submitted an Investigational New Drug (IND) application for a Class I new drug—the "Influenza Virus Subunit Vaccine (Adjuvanted)"—which has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This approval marks the completion of the company’s full pipeline coverage for subunit influenza vaccines, including both trivalent and quadrivalent formulations, offering tailored options for diverse age groups and populations with specific needs.
IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly submitted an Investigational New Drug (IND) application for a Class I new drug—the "Influenza Virus Subunit Vaccine (Adjuvanted)"—which has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This approval marks the completion of the company’s full pipeline coverage for subunit influenza vaccines, including both trivalent and quadrivalent formulations, offering tailored options for diverse age groups and populations with specific needs.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-30 14:49
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly submitted an Investigational New Drug (IND) application for a Class I new drug—the "Influenza Virus Subunit Vaccine (Adjuvanted)"—which has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This approval marks the completion of the company’s full pipeline coverage for subunit influenza vaccines, including both trivalent and quadrivalent formulations, offering tailored options for diverse age groups and populations with specific needs.
Source: Official Website of the Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA)
Currently, the influenza virus remains one of the most significant respiratory pathogens threatening global public health. Seasonal outbreaks or sporadic cross-species transmission and pandemics significantly impact human health and socioeconomic development. Compared to other age groups, the elderly face higher infection rates and greater risks of severe illness or death from influenza, with risks escalating with age. Both the World Health Organization (WHO) and the Chinese Center for Disease Control and Prevention (China CDC) recommend the elderly as a priority group for influenza vaccination.
The newly approved trivalent influenza virus subunit vaccine (adjuvanted), developed by Ab&B Bio, aligns with WHO recommendations and leverages the company’s proven platform technology and novel adjuvant formulations. It is specifically designed for individuals aged 65 and older. Preclinical studies demonstrate that this adjuvanted vaccine significantly elevates antibody levels and neutralizing antibody titers, offering superior immune response enhancement—making it the optimal choice for elderly populations vulnerable to influenza.
Relevant information
-
Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session.On August 5, 2026, a delegation comprising leaders and experts from the Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio-Tech CO.,LTD.JS to conduct an on-site inspection and hold a symposium. During the meeting, both parties engaged in in-depth discussions on topics such as innovative vaccine R&D, clinical evaluation, joint construction of technical platforms, sharing of data resources, talent cultivation, and technology commercialization, thereby accelerating the transition of their strategic cooperation from "paper-based consensus" to "substantive implementation." - The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States. 07-02
- Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
